Domov › Množni mielom › Texas › Dallas
Klinične študije za Množni mielom v Dallas, TX
17 študij za Množni mielom išče udeležence na lokacijah v Dallas in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Vključevanje udeležencevFaza 3
- Research Site, Dallas
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 3
- Baylor University Medical Center, Dallas
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 3
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center, Dallas
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Vključevanje udeležencevFaza 3
- University of Texas Southwestern Medical Center, Dallas
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 2
- UT Southwestern Medical Center, Dallas
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Vključevanje udeležencevFaza 1/2
- University of Texas - Southwestern Medical Center /ID# 271914, Dallas
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Vključevanje udeležencevFaza 3
- Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
- Baylor University Medical Center, Dallas
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Vključevanje udeležencevFaza 1/2
- Research Site, Dallas
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Vključevanje udeležencevFaza 3
- Research Site, Dallas
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Vključevanje udeležencevFaza 1
- Baylor University Medical Center, Dallas
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Vključevanje udeležencevFaza 1/2
- University of Texas - Southwestern Medical Center /ID# 274360, Dallas
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Vključevanje udeležencevFaza 1
- University of Texas Southwestern, Dallas
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Vključevanje udeležencevFaza 2
- University of Texas Southwestern, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Vključevanje udeležencevOpazovalna študija
- Ut Southwestern, Dallas
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- University of Texas Southwestern Medical Center, Dallas
Študije za Množni mielom v drugih mestih
- New York City, NY60 študij
- Boston, MA42 študij
- Atlanta, GA41 študij
- Houston, TX38 študij
- Durham, NC37 študij
- Nashville, TN32 študij
- Denver, CO27 študij
- Rochester, MN24 študij
- St. Louis, MO24 študij
- Columbus, OH24 študij
- Baldwin Park, CA23 študij
- Chicago, IL22 študij
Druge študije v Dallas
- Rak dojke55 študij
- Nemalicelični pljučni rak52 študij
- Metastatski rak42 študij
- Srčno popuščanje42 študij
- Rak (vse vrste)37 študij
- Rak prostate36 študij
- Kolorektalni rak33 študij
- Debelost30 študij
- Rak jajčnikov28 študij
- Rak mehurja27 študij
- Rak pljuč27 študij
- Rak endometrija24 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.